Building rendering of a new, state-of-the-art subject and innovation halfway astatine Amgen's planetary office successful Thousand Oaks, California.
Courtesy: Amgen
Amgen connected Tuesday said it volition walk much than $600 cardinal to physique a caller probe and improvement installation astatine its office successful Thousand Oaks, California, the latest successful a drawstring of new U.S. investments by the pharmaceutical industry.
Drugmakers person been scrambling to boost their beingness successful the U.S. arsenic President Donald Trump threatens to clamp down connected the manufacture with tariffs connected pharmaceuticals imported into the country. Trump has said those levies volition incentivize companies to re-shore accumulation astatine a clip erstwhile home cause manufacturing has shrunk dramatically implicit the past decade.
In a release, Amgen said operation of the installation volition statesman successful the 3rd 4th of this twelvemonth and volition make hundreds of U.S. jobs.
Notably, the installation is not a manufacturing plant, but it volition let researchers, engineers and scientists to collaborate connected uncovering next-generation drugs for patients with "the astir superior diseases," according to the company. Amgen said the gathering features "advanced automation and integer capabilities," which volition springiness scientists the indispensable tools for that probe and development.
"At Amgen, we're continuing to put successful the aboriginal of American subject and innovation," CEO Bob Bradway said successful the release. "The halfway volition empower our scientists with the tools and collaborative situation they request to signifier the adjacent epoch of technological find and beforehand medicines that amended quality health."
Amgen said that since the transition of the Tax Cuts and Jobs Act of 2017, it has invested astir $5 cardinal successful nonstop U.S. superior expenditures. In April, the institution announced a $900 cardinal enlargement of its Ohio biotech manufacturing facility. In December, the drugmaker announced it would spend $1 billion to physique a 2nd cause substance works successful Holly Springs, North Carolina.
Those investments travel aft the U.S. Food and Drug Administration successful August launched a program that aims to marque it easier for companies to acceptable up caller cause manufacturing plants successful the U.S. The White House estimates it tin presently instrumentality 5 to 10 years to physique caller manufacturing capableness for pharmaceuticals, which it previously called "unacceptable from a national-security standpoint."
English (US) ·